Delving into the Latest Updates on Hubei Huazhong Pharmaceutical Co. Ltd. with Synapse

Overview

Tags

Other Diseases

Infectious Diseases

Skin and Musculoskeletal Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	10
Nervous System Diseases	6
Neoplasms	2
Endocrinology and Metabolic Disease	2
Immune System Diseases	2
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Small molecule drug	16

Top 5 Target	Count

50S subunit(50S ribosomal subunit)	3
GABAA receptor(Gamma-aminobutyric acid A receptor)	2
COX(Cyclooxygenases)	1
Tubulin	1
ER(Estrogen receptors)	1

研究健康受试者空腹单次口服受试制剂沙库巴曲缬沙坦钠片（华中药业股份有限公司，规格：50mg，沙库巴曲/缬沙坦（24mg/26mg））与参比制剂沙库巴曲缬沙坦钠片（商品名：诺欣妥®，Novartis Pharma Schweiz AG，规格：50mg，沙库巴曲/缬沙坦（24mg/26mg）)在吸收程度和速度方面是否存在差异，评价受试制剂和参比制剂在空腹状态下给药时的生物等效性，观察受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

To investigate whether there are differences in the extent and rate of absorption between the test preparation sacubitril-valsartan sodium tablets (Huazhong Pharmaceutical Co., Ltd., specification: 50 mg, sacubitril/valsartan (24 mg/26 mg)) and the reference preparation sacubitril-valsartan sodium tablets (trade name: Nusintuo®, Novartis Pharma Schweiz AG, specification: 50 mg, sacubitril/valsartan (24 mg/26 mg)) after a single oral administration on an empty stomach in healthy subjects, to evaluate the bioequivalence of the test preparation and the reference preparation when administered in the fasting state, and to observe the safety of the test preparation and the reference preparation in healthy subjects.

Start Date04 Jun 2024

Sponsor / Collaborator

Hubei Huazhong Pharmaceutical Co. Ltd.

CTR20241573 / Active, not recruitingNot Applicable

中国健康受试者空腹及餐后状态下单次口服沙库巴曲缬沙坦钠片的单中心、开放、随机、两制剂、两序列、四周期、完全重复交叉人体生物等效性试验

[Translation] A single-center, open-label, randomized, two-dose, two-sequence, four-period, fully repeated crossover bioequivalence study of sacubitril-valsartan sodium tablets in Chinese healthy volunteers in the fasting and fed state

研究健康受试者空腹及餐后单次口服受试制剂沙库巴曲缬沙坦钠片（华中药业股份有限公司，规格：200mg，沙库巴曲/缬沙坦（97mg/103mg））与参比制剂沙库巴曲缬沙坦钠片（商品名：诺欣妥®，Novartis Pharma Schweiz AG，规格：200mg，沙库巴曲/缬沙坦（97mg/103mg））在吸收程度和速度方面是否存在差异，评价受试制剂和参比制剂在空腹及餐后状态下给药时的生物等效性性，观察受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

To investigate whether there are differences in the extent and rate of absorption between the test preparation sacubitril-valsartan sodium tablets (Huazhong Pharmaceutical Co., Ltd., specification: 200 mg, sacubitril/valsartan (97 mg/103 mg)) and the reference preparation sacubitril-valsartan sodium tablets (trade name: Entresto®, Novartis Pharma Schweiz AG, specification: 200 mg, sacubitril/valsartan (97 mg/103 mg)) after a single oral administration on an empty stomach or after a meal in healthy subjects, to evaluate the bioequivalence of the test preparation and the reference preparation when administered on an empty stomach or after a meal, and to observe the safety of the test preparation and the reference preparation in healthy subjects.

Start Date26 May 2024

Sponsor / Collaborator

Hubei Huazhong Pharmaceutical Co. Ltd.

CTR20233960 / Active, not recruitingNot Applicable

中国健康受试者空腹及餐后状态下单次口服沙库巴曲缬沙坦钠片的单中心、开放、随机、两制剂、两序列、四周期、完全重复交叉人体生物等效性预试验

[Translation] A single-center, open-label, randomized, two-dose, two-sequence, four-period, fully repeated crossover bioequivalence pilot study in healthy Chinese volunteers after a single oral dose of sacubitril-valsartan sodium tablets in the fasting and fed state

研究健康受试者空腹及餐后单次口服受试制剂沙库巴曲缬沙坦钠片（华中药业股份有限公司，规格：200mg，沙库巴曲/缬沙坦（97mg/103mg））与参比制剂沙库巴曲缬沙坦钠片（商品名：诺欣妥 ®，Novartis Pharma Schweiz AG，规格：200mg，沙库巴曲/缬沙坦（97mg/103mg））在吸收程度和速度方面是否存在差异，评价受试制剂和参比制剂在空腹及餐后状态下给药时的生物等效性趋势，为正式试验提供依据，观察受试制剂和参比制剂在健康受试者中的安全性。

[Translation]

To study whether there are differences in the extent and rate of absorption of the test preparation sacubitril-valsartan sodium tablets (Huazhong Pharmaceutical Co., Ltd., specification: 200 mg, sacubitril/valsartan (97 mg/103 mg)) and the reference preparation sacubitril-valsartan sodium tablets (trade name: Entresto ®, Novartis Pharma Schweiz AG, specification: 200 mg, sacubitril/valsartan (97 mg/103 mg)) after a single oral administration on an empty stomach or after a meal in healthy subjects, to evaluate the bioequivalence trend of the test preparation and the reference preparation when administered on an empty stomach or after a meal, to provide a basis for formal trials, and to observe the safety of the test preparation and the reference preparation in healthy subjects.

Start Date17 Dec 2023

Sponsor / Collaborator

Hubei Huazhong Pharmaceutical Co. Ltd.

100 Clinical Results associated with Hubei Huazhong Pharmaceutical Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Hubei Huazhong Pharmaceutical Co. Ltd.

Login to view more data

1

Literatures (Medical) associated with Hubei Huazhong Pharmaceutical Co. Ltd.

Zhongguo Xiandai Zhongyao

Determination of total flavonol glycosides and terpene lactones in Xinghong particles

Author: Zhao, Cheng-an

The objective of the paper is to detect the total flavonol glycosides and terpene lactones in Xinghong particles.HPLC was adopted and its conditions were as follows: BDS C₁₈ column (250 mm × 4.6 mm, 5 μm), symmetry shield C₁₈(3.9 mm × 150 mm, 5 μm), the mobile phase of methanol-0.4% phosphate (55:45) Pr alc.-tetrahydrofuran-water(1:15:84), solution flow rate of 1.0 mL/min^-1, detection wavelength was at 360 nm and evaporative light scattering detector.Quercetin, kaempferide, isorhamnetin and bilobalide A, B, C could be completely separated and had good linearity.The method is rapid, reliable and accurate, and could be used for quality control of Xinghong particles.

100 Deals associated with Hubei Huazhong Pharmaceutical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Hubei Huazhong Pharmaceutical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

1

15

Approved

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Albendazole ( Microtubule-associated proteins )	Helminthiasis More	Approved
Naproxen ( COX )	Gout More	Approved
Lincomycin Hydrochloride ( 50S subunit )	Bacterial Infections More	Approved
Berberine Chloride Hydrate	Intestinal infections More	Approved
Nitrazepam ( GABAA receptor )	Sleep Initiation and Maintenance Disorders More	Approved